Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Geriatrics and Gerontology
Reference44 articles.
1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in onoclogy (NCCN guidelines): prostate cancer (version 1.2015). 2015. http://www.nccn.org/ . Accessed 9 Feb 2015.
2. Bastos DA, Dzik C, Rathkopf D, et al. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Oncology. 2014;28(8):693–9.
3. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–90.
4. Sanford M. Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer. Drugs. 2013;73(15):1723–32.
5. Guerrero J, Alfaro IE, Gómez F, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013;73(12):1291–305.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献